EDUCATIONAL NOTICE: Peptidings provides information for educational and research purposes only. The compounds discussed on this page are subjects of ongoing scientific investigation at varying stages of development. None of the information presented here constitutes medical advice or a recommendation for use. Consult a qualified healthcare provider before making any decisions about peptide use.
Browse by Condition
Weight Loss Resistance
Weight loss is where the peptide world meets mainstream medicine—and where the evidence is strongest. This conditions page collects every compound on Peptidings with published research relevant to weight management, metabolic dysfunction, and body composition. The range is extraordinary: from semaglutide’s 17,604-patient cardiovascular outcomes trial to a mitochondrial peptide fragment with zero human data.
Four FDA-approved drugs anchor this page—three broad-spectrum GLP-1/multi-agonists and one precision drug for rare genetic obesity. Below them, the evidence thins into clinical-stage pipeline compounds, growth hormone secretagogues used off-label for body composition, and preclinical molecules adopted by the biohacking community based on rodent data alone.
Condition at a Glance
|
14 Compounds Researched |
5 FDA Approved |
5 Clinical Trials |
4 Preclinical |
|
Approved Drug FDA-approved or equivalent regulatory approval |
Clinical Trials Human clinical trial data (Phase I+) |
Preclinical Only Animal models and cell culture only |
BLUF: Bottom Line Up Front
This is the best-studied condition in the Peptidings library. Semaglutide (Wegovy), tirzepatide (Zepbound), and liraglutide (Saxenda) are the approved broad-spectrum obesity drugs with tens of thousands of patients in controlled trials. Setmelanotide (Imcivree) is FDA-approved specifically for rare genetic obesity (POMC, PCSK1, LEPR deficiency, Bardet-Biedl syndrome). Pipeline multi-agonists—orforglipron (oral), survodutide (GCG/GLP-1), retatrutide (triple agonist), and cagrisema (GLP-1/amylin)—have reported Phase 2/3 weight loss between 15% and 24%. Tesamorelin is FDA-approved for HIV-associated visceral fat. MK-677 affects body composition but does not reduce body weight. AOD-9604, 5-Amino-1MQ, HGH Fragment 176-191, and MOTS-C have essentially no human weight-loss evidence.
Compounds Researched for This Condition
14 compounds with published research relevant to weight loss resistance. Evidence tiers reflect the strength of research for this specific condition—not the compound’s highest overall tier.
Group 1 of 4
The Approved Obesity Drugs
Four FDA-approved medications for weight management—three broad-spectrum GLP-1/multi-agonists and one precision drug for rare genetic obesity syndromes.
Group 2 of 4
The Pipeline Multi-Agonists
Four compounds in active clinical trials that extend or combine the GLP-1 mechanism—oral delivery, glucagon co-agonism, and dual GLP-1/amylin combinations.
|
|
|
||||||||||||
|
Group 3 of 4
The Body Composition Compounds
Growth hormone axis compounds used for body composition rather than direct weight loss—they affect the ratio of fat to lean mass more than total body weight.
|
|
Group 4 of 4
The Preclinical Self-Experimenters
Compounds adopted by the biohacking community for weight loss based on rodent data, with minimal or zero human clinical evidence.
|
|
|
||||||||||||
|
What the Research Landscape Looks Like
The weight loss research landscape has two dramatically different neighborhoods. On one side, the GLP-1 revolution: four approved broad-spectrum drugs plus four pipeline multi-agonists that represent one of the most successful drug development programs in pharmaceutical history. These are real drugs with real data in real patients—the kind of evidence base most peptide clusters can only dream of. Setmelanotide sits apart as a precision drug for a specific genetic population, not general obesity.
On the other side, compounds like AOD-9604, 5-Amino-1MQ, HGH Fragment 176-191, and MOTS-C, which have essentially no human evidence for weight loss but are widely sold and self-administered. The growth hormone secretagogues (MK-677, Tesamorelin) sit in between—real clinical data, but for body composition rather than weight loss per se. MK-677 actually increases appetite, which is the opposite of what most people want from a ‘weight loss peptide.’
| Mechanism | Compounds |
|
GLP-1 Receptor Agonism Mimicking the gut hormone GLP-1 to reduce appetite, slow gastric emptying, and improve insulin sensitivity—the dominant mechanism in modern obesity pharmacotherapy. |
Semaglutide, Tirzepatide, Liraglutide, Orforglipron, Survodutide, Retatrutide, CagriSema |
|
Melanocortin-4 Receptor Agonism Activating MC4R signaling downstream of leptin—the central appetite regulation pathway disrupted in rare genetic obesity. |
Setmelanotide |
|
Growth Hormone Axis Modulation Stimulating growth hormone release to improve the ratio of lean mass to fat mass—body recomposition rather than weight reduction. |
MK-677, Tesamorelin, HGH Fragment 176-191, AOD-9604 |
|
Mitochondrial & Metabolic Enzyme Targeting Preclinical mechanisms targeting cellular energy metabolism, fat storage enzymes, and mitochondrial function—none with human validation for weight loss. |
5-Amino-1MQ, MOTS-C |
Plain English
The weight loss story is dominated by GLP-1 drugs—they mimic a gut hormone that makes you feel full. Three broad-spectrum drugs are FDA-approved for weight loss (Wegovy, Zepbound, Saxenda), four more are in late-stage trials, and one drug (Imcivree) is approved for rare genetic obesity only. They work. Everything else on this page either targets body composition instead of weight (the GH compounds) or has minimal proof it does anything in humans (AOD-9604, 5-Amino-1MQ, HGH Fragment 176-191, MOTS-C). The evidence gap between the GLP-1s and everything else is the widest on any conditions page.
Related Research
Research Clusters Covering These Compounds
|
Weight Loss & Metabolic Peptides The primary cluster—from approved GLP-1 drugs to preclinical mitochondrial peptides. |
Growth Hormone Secretagogues GH axis compounds affecting body composition, including MK-677 and Tesamorelin. |
Tanning & Melanocortin Peptides Setmelanotide and the broader melanocortin family that regulates appetite and pigmentation. |
Disclaimer: This page is for educational and research purposes only. It does not constitute medical advice, diagnosis, or treatment. The compounds discussed are subjects of ongoing scientific research and have not been evaluated by the FDA for all applications described. Consult a qualified healthcare provider before making any decisions about your health.